According to WHO data published in July 2021, 296 million individuals worldwide were living with chronic hepatitis B virus by 2019, with 1.5 million new infections each year. The highest rates of Hepatitis B infection are found in the WHO regions of the West Pacific and Africa, where 6.2 percent and 6.1 percent of people, respectively, are affected. Inflammation of the liver is referred to as hepatitis. Inflammation is the body's reaction to irritation or injury, and it usually causes swelling and pain
Frequently Asked Questions
The market is segmented based on Segmentation, By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Others), Treatment (Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Others), Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032.
.
The Global Viral Hepatitis Market size was valued at USD 16.61 USD Billion in 2024.
The Global Viral Hepatitis Market is projected to grow at a CAGR of 3.5% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
